Achillion shares spike on promising hep C data

Shares of Achillion Pharmaceuticals jumped 22 percent after the developer announced that preliminary data from an early-stage trial demonstrated that its hepatitis C drug was effective on a once-daily dose using a lower dosage. ACH-1625 spurred meaningful drops in virus levels after five days of treatment. "We remain very encouraged by these compelling results and look forward to advancing the drug into Phase 2 studies in the coming months," Chief Executive Michael Kishbauch said in a statement. Achillion release | Report

Suggested Articles

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.